Jácome AA, Coutinho AK, Lima EM, Andrade AC, Dos Santos JS. Personalised medication in gastric most cancers: the place are we and the place are we going? World J Gastroenterol. 2016;22(3):1160–71.
Lee J, Bass AJ, Ajani JA. Gastric adenocarcinoma: An replace on genomics, immune system modulations, and focused remedy. American society of Medical Oncology academic ebook American Society of Medical Oncology Annual Assembly 2016, 35:104–111.
Zhou W, Ma L, Yang J, Qiao H, Li L, Guo Q, Ma J, Zhao L, Wang J, Jiang G, et al. Potent and particular MTH1 inhibitors focusing on gastric most cancers. Cell Demise Dis. 2019;10(6):434.
Gad H, Koolmeister T, Jemth AS, Eshtad S, Jacques SA, Strom CE, Svensson LM, Schultz N, Lundback T, Einarsdottir BO, et al. MTH1 inhibition eradicates most cancers by stopping sanitation of the dNTP pool. Nature. 2014;508(7495):215–21.
Burton DG, Rai P. MTH1 counteracts oncogenic oxidative stress. Oncoscience. 2015;2(10):785–6.
Storz P. Reactive oxygen species in tumor development. Entrance Bioscience: J Digital Libr. 2005;10:1881–96.
Ishikawa Ok, Takenaga Ok, Akimoto M, Koshikawa N, Yamaguchi A, Imanishi H, Nakada Ok, Honma Y, Hayashi J. ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Sci (New York NY). 2008;320(5876):661–4.
Ramsey MR, Sharpless NE. ROS as a tumour suppressor? Nat Cell Biol. 2006;8(11):1213–5.
Cooke MS, Evans MD, Dizdaroglu M, Lunec J. Oxidative DNA harm: mechanisms, mutation, and illness. FASEB Journal: Official Publication Federation Am Soc Experimental Biology. 2003;17(10):1195–214.
Fujikawa Ok, Kamiya H, Yakushiji H, Fujii Y, Nakabeppu Y, Kasai H. The oxidized types of dATP are substrates for the human MutT homologue, the hMTH1 protein. J Biol Chem. 1999;274(26):18201–5.
Oka S, Ohno M, Tsuchimoto D, Sakumi Ok, Furuichi M, Nakabeppu Y. Two distinct pathways of cell demise triggered by oxidative harm to nuclear and mitochondrial DNAs. EMBO J. 2008;27(2):421–32.
Yoshimura D, Sakumi Ok, Ohno M, Sakai Y, Furuichi M, Iwai S, Nakabeppu Y. An oxidized purine nucleoside triphosphatase, MTH1, suppresses cell demise attributable to oxidative stress. J Biol Chem. 2003;278(39):37965–73.
Martinez Molina D, Jafari R, Ignatushchenko M, Seki T, Larsson EA, Dan C, Sreekumar L, Cao Y, Nordlund P. Monitoring drug goal engagement in cells and tissues utilizing the mobile thermal shift assay. Sci (New York NY). 2013;341(6141):84–7.
Li L, Track L, Liu X, Yang X, Li X, He T, Wang N, Yang S, Yu C, Yin T, et al. Synthetic Virus delivers CRISPR-Cas9 system for genome enhancing of cells in mice. ACS Nano. 2017;11(1):95–111.
Huber KV, Salah E, Radic B, Gridling M, Elkins JM, Stukalov A, Jemth AS, Göktürk C, Sanjiv Ok, Strömberg Ok, et al. Stereospecific focusing on of MTH1 by (S)-crizotinib as an anticancer technique. Nature. 2014;508(7495):222–7.
Samaranayake GJ, Huynh M, Rai P. MTH1 as a chemotherapeutic goal: the Elephant within the room. Cancers 2017, 9(5).
Papeo G. MutT homolog 1 (MTH1): the silencing of a goal. J Med Chem. 2016;59(6):2343–5.
Wang JY, Liu GZ, Wilmott JS, La T, Feng YC, Yari H, Yan XG, Thorne RF, Scolyer RA, Zhang XD, et al. Skp2-Mediated stabilization of MTH1 promotes survival of Melanoma cells upon oxidative stress. Most cancers Res. 2017;77(22):6226–39.
Pal A, Younger MA, Donato NJ. Rising potential of therapeutic focusing on of ubiquitin-specific proteases within the remedy of most cancers. Most cancers Res. 2014;74(18):4955–66.
Suresh B, Lee J, Kim H, Ramakrishna S. Regulation of pluripotency and differentiation by deubiquitinating enzymes. Cell Demise Differ. 2016;23(8):1257–64.
Homan CC, Kumar R, Nguyen LS, Haan E, Raymond FL, Abidi F, Raynaud M, Schwartz CE, Wooden SA, Gecz J, et al. Mutations in USP9X are related to X-linked mental incapacity and disrupt neuronal cell migration and progress. Am J Hum Genet. 2014;94(3):470–8.
Chen Z, Wang HW, Wang S, Fan L, Feng S, Cai X, Peng C, Wu X, Lu J, Chen D, et al. USP9X deubiquitinates ALDH1A3 and maintains mesenchymal id in glioblastoma stem cells. J Clin Investig. 2019;129(5):2043–55.
Engel Ok, Rudelius M, Slawska J, Jacobs L, Ahangarian Abhari B, Altmann B, Kurutz J, Rathakrishnan A, Fernández-Sáiz V, Brunner A, et al. USP9X stabilizes XIAP to manage mitotic cell demise and chemoresistance in aggressive B-cell lymphoma. EMBO Mol Med. 2016;8(8):851–62.
Li L, Liu T, Li Y, Wu C, Luo Ok, Yin Y, Chen Y, Nowsheen S, Wu J, Lou Z, et al. The deubiquitinase USP9X promotes tumor cell survival and confers chemoresistance by YAP1 stabilization. Oncogene. 2018;37(18):2422–31.
Khan OM, Carvalho J, Spencer-Dene B, Mitter R, Frith D, Snijders AP, Wooden SA, Behrens A. The deubiquitinase USP9X regulates FBW7 stability and suppresses colorectal most cancers. J Clin Investig. 2018;128(4):1326–37.
Fu X, Xie W, Track X, Wu Ok, Xiao L, Liu Y, Zhang L. Aberrant expression of deubiquitylating enzyme USP9X predicts poor prognosis in gastric most cancers. Clin Res Hepatol Gastroenterol. 2017;41(6):687–92.
Akiyama H, Umezawa Y, Ishida S, Okada Ok, Nogami A, Miura O. Inhibition of USP9X induces apoptosis in FLT3-ITD-positive AML cells cooperatively by inhibiting the mutant kinase by aggresomal translocation and inducing oxidative stress. Most cancers Lett. 2019;453:84–94.
Marx C, Held JM, Gibson BW, Benz CC. ErbB2 trafficking and degradation related to K48 and K63 polyubiquitination. Most cancers Res. 2010;70(9):3709–17.
Guo N, Peng Z. MG132, a proteasome inhibitor, induces apoptosis in tumor cells. Asia Pac J Clin Oncol. 2013;9(1):6–11.
Fouquerel E, Lormand J, Bose A, Lee HT, Kim GS, Li J, Sobol RW, Freudenthal BD, Myong S, Opresko PL. Oxidative guanine base harm regulates human telomerase exercise. Nat Struct Mol Biol. 2016;23(12):1092–100.
Hamanaka RB, Chandel NS. Mitochondrial reactive oxygen species regulate mobile signaling and dictate organic outcomes. Developments Biochem Sci. 2010;35(9):505–13.
Akiyama S, Saeki H, Nakashima Y, Iimori M, Kitao H, Oki E, Oda Y, Nakabeppu Y, Kakeji Y, Maehara Y. Prognostic impression of MutT homolog-1 expression on esophageal squamous cell carcinoma. Most cancers Med. 2017;6(1):258–66.
Borrego S, Vazquez A, Dasí F, Cerdá C, Iradi A, Tormos C, Sánchez JM, Bagán L, Boix J, Zaragoza C, et al. Oxidative stress and DNA harm in human gastric carcinoma: 8-Oxo-7’8-dihydro-2’-deoxyguanosine (8-oxo-dG) as a doable tumor marker. Int J Mol Sci. 2013;14(2):3467–86.
Chen MY, Li ZP, Solar ZN, Ma M. USP9X promotes the development of hepatocellular carcinoma by regulating beta-catenin. Ir J Med Sci. 2020;189(3):865–71.
Li X, Track N, Liu L, Liu X, Ding X, Track X, Yang S, Shan L, Zhou X, Su D, et al. USP9X regulates centrosome duplication and promotes breast carcinogenesis. Nat Commun. 2017;8:14866.
Potu H, Peterson LF, Kandarpa M, Pal A, Solar H, Durham A, Harms PW, Hollenhorst PC, Eskiocak U, Talpaz M, et al. Usp9x regulates Ets-1 ubiquitination and stability to manage NRAS expression and tumorigenicity in melanoma. Nat Commun. 2017;8:14449.
Pérez-Mancera PA, Rust AG, van der Weyden L, Kristiansen G, Li A, Sarver AL, Silverstein KA, Grützmann R, Aust D, Rümmele P, et al. The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature. 2012;486(7402):266–70.
Peng J, Hu Q, Liu W, He X, Cui L, Chen X, Yang M, Liu H, Wei W, Liu S, et al. USP9X expression correlates with tumor development and poor prognosis in esophageal squamous cell carcinoma. Diagn Pathol. 2013;8:177.
Wang Y, Liu Y, Yang B, Cao H, Yang CX, Ouyang W, Zhang SM, Yang GF, Zhou FX, Zhou YF, et al. Elevated expression of USP9X correlates with poor prognosis in human non-small cell lung most cancers. J Thorac Illness. 2015;7(4):672–9.
Peddaboina C, Jupiter D, Fletcher S, Yap JL, Rai A, Tobin RP, Jiang W, Rascoe P, Rogers MK, Smythe WR, et al. The downregulation of Mcl-1 through USP9X inhibition sensitizes stable tumors to bcl-xl inhibition. BMC Most cancers. 2012;12:541.
Moukengue B, Brown HK, Charrier C, Battaglia S, Baud’huin M, Quillard T, Pham TM, Pateras IS, Gorgoulis VG, Helleday T, et al. TH1579, MTH1 inhibitor, delays tumour progress and inhibits metastases growth in osteosarcoma mannequin. EBioMedicine. 2020;53:102704.
Warpman Berglund U, Sanjiv Ok, Gad H, Kalderen C, Koolmeister T, Pham T, Gokturk C, Jafari R, Maddalo G, Seashore-Ludlow B, et al. Validation and growth of MTH1 inhibitors for remedy of most cancers. Ann Oncol. 2016;27(12):2275–83.
Zhan D, Zhang X, Li J, Ding X, Cui Y, Jia J. MTH1 inhibitor TH287 suppresses gastric Most cancers Improvement by the regulation of PI3K/AKT signaling. Most cancers Biother Radiopharm. 2020;35(3):223–32.
Helleday T. Mitotic MTH1 inhibitors in remedy of Most cancers. Most cancers Deal with Res. 2023;186:223–37.
Kim S, Woo SM, Min KJ, Search engine optimization SU, Lee TJ, Kubatka P, Kim DE, Kwon TK. WP1130 enhances TRAIL-Induced apoptosis by USP9X-Dependent mir-708-Mediated downregulation of c-FLIP. Cancers (Basel) 2019, 11(3).
